Protara Therapeutics Inc (TARA)

May 04, 2026

Will New Bladder Cancer Data Revive Protara's Momentum? - RTTNews

May 04, 2026

May 04, 2026

One Protara Therapeutics Insider Raised Their Stake In The Previous Year - Yahoo Finance

May 04, 2026

Apr 29, 2026

Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA) - The Globe and Mail

Apr 29, 2026

Apr 29, 2026

H.C. Wainwright Maintains Protara Therapeutics(TARA.US) With Buy Rating, Raises Target Price to $27 - Moomoo

Apr 29, 2026

Apr 29, 2026

TARA Maintained by HC Wainwright & Co. -- Price Target Raised to $27 - GuruFocus

Apr 29, 2026

Apr 28, 2026

TD Cowen Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $30 - Moomoo

Apr 28, 2026

Apr 28, 2026

[ARS] Protara Therapeutics, Inc. SEC Filing - Stock Titan

Apr 28, 2026

Apr 28, 2026

Protara Therapeutics (TARA) seeks more shares, officer protections in 2026 vote - Stock Titan

Apr 28, 2026

Apr 27, 2026

Protara, Ceribell rise on FDA breakthrough designations - MSN

Apr 27, 2026

Apr 27, 2026

Protara to present bladder cancer trial data at AUA meeting By Investing.com - Investing.com Canada

Apr 27, 2026

Apr 27, 2026

BlackRock (TARA) reports 3,387,459 shares, 6.3% stake (Schedule 13G) - Stock Titan

Apr 27, 2026

Apr 27, 2026

Bladder cancer trial update from 31 patients goes to urology meeting - Stock Titan

Apr 27, 2026

Apr 27, 2026

Protara Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

Apr 27, 2026

Apr 26, 2026

Protara announces proposed public offering - MSN

Apr 26, 2026

Apr 26, 2026

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Apr 26, 2026

Apr 23, 2026

TARA (NASDAQ: TARA) files Form 144 listing multiple proposed share sales - Stock Titan

Apr 23, 2026

Apr 23, 2026

Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN

Apr 23, 2026

Apr 22, 2026

Protara Therapeutics (TARA) Market Position | Q4 2025: EPS Misses ViewsWall Street Picks - Cổng thông tin điện tử Tỉnh Sơn La

Apr 22, 2026

Apr 18, 2026

Protara Therapeutics Inc stock (US87612E1064): Is its rare disease pipeline strong enough to drive i - AD HOC NEWS

Apr 18, 2026

Apr 17, 2026

Protara Therapeutics (NASDAQ: TARA) seeks approval to double authorized shares to 200M - Stock Titan

Apr 17, 2026

Apr 15, 2026

Protara's experimental bladder cancer drug shows encouraging results - MSN

Apr 15, 2026

Apr 14, 2026

Protara Therapeutics Inc stock (US87612E1064): Is its rare disease pipeline strong enough to unlock - AD HOC NEWS

Apr 14, 2026

Apr 13, 2026

Published on: 2026-04-14 02:30:36 - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Exit Recap: Can Protara Therapeutics Inc beat the S P 5002026 Institutional & Low Risk High Win Rate Stock Picks - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

Retail Trends: Can Protara Therapeutics Inc beat the S P 5002026 Institutional Moves & Low Drawdown Momentum Ideas - baoquankhu1.vn

Apr 12, 2026

Apr 12, 2026

Analyst Upgrade: Will Protara Therapeutics Inc benefit from government policyMarket Sentiment Summary & Weekly High Potential Stock Alerts - baoquankhu1.vn

Apr 12, 2026

Apr 10, 2026

Zummo, Protara Therapeutics chief R&D officer, sells $6k in stock - Investing.com Australia

Apr 10, 2026

Apr 09, 2026

Insider Sell: Jacqueline Zummo Sells Shares of Protara Therapeutics Inc (TARA) - GuruFocus

Apr 09, 2026

Apr 09, 2026

Zummo, Protara Therapeutics chief R&D officer, sells $6k in stock By Investing.com - Investing.com South Africa

Apr 09, 2026

Apr 09, 2026

Protara Therapeutics (TARA) R&D chief sells 1,134 shares under 10b5-1 plan - Stock Titan

Apr 09, 2026

Apr 09, 2026

Is Protara Therapeutics (TARA) Stock Underperforming | Price at $5.17, Down 0.98%Attention Stocks - Cổng thông tin điện tử tỉnh Lào Cai

Apr 09, 2026

Apr 08, 2026

Quarterly Risk: Is Protara Therapeutics Inc trading at a discountBuy Signal & Fast Exit Strategy with Risk Control - baoquankhu1.vn

Apr 08, 2026

Apr 08, 2026

Stock Traders Buy Large Volume of Protara Therapeutics Call Options (NASDAQ:TARA) - MarketBeat

Apr 08, 2026

Apr 08, 2026

Sentiment Review: Whats Protara Therapeutics Incs historical returnWeekly Trading Summary & Reliable Breakout Stock Forecasts - baoquankhu1.vn

Apr 08, 2026

Apr 06, 2026

JonesTrading Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $25 - Moomoo

Apr 06, 2026

Apr 05, 2026

Investor Mood: Can Protara Therapeutics Inc deliver consistent EPS growth2026 Volatility Report & Capital Protection Trading Alerts - baoquankhu1.vn

Apr 05, 2026

Apr 03, 2026

TARA Stock Analysis: Protara Therapeutics biotech posts 1.39 percent gain at 5.11 dollar level - Cổng thông tin điện tử tỉnh Lào Cai

Apr 03, 2026

Apr 02, 2026

Insider Sell: Jacqueline Zummo Sells 22,598 Shares of Protara Th - GuruFocus

Apr 02, 2026

Apr 02, 2026

Insider Selling: Protara Therapeutics (NASDAQ:TARA) Insider Sells 22,598 Shares of Stock - MarketBeat

Apr 02, 2026

Apr 02, 2026

Protara (TARA) Chief R&D Officer sells 22,598 shares under 10b5-1 plan - Stock Titan

Apr 02, 2026

Apr 01, 2026

[144] Protara Therapeutics, Inc. SEC Filing - Stock Titan

Apr 01, 2026

Apr 01, 2026

TARA Stock Analysis: Protara Therapeutics Inc. 0.96% Daily Dip Near $5.16 Trend Review - Xã Thanh Hà

Apr 01, 2026

Apr 01, 2026

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Apr 01, 2026

Mar 31, 2026

Risk Hedge: What is the target price for Protara Therapeutics Inc stock2026 Trading Recap & Momentum Based Trading Ideas - baoquankhu1.vn

Mar 31, 2026

Mar 30, 2026

Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results - TipRanks

Mar 30, 2026

Mar 30, 2026

Protara Therapeutics reports six-month response rate in bladder cancer trial - Investing.com

Mar 30, 2026

Mar 30, 2026

Protara Therapeutics reports six-month response rate in bladder cancer trial By Investing.com - Investing.com South Africa

Mar 30, 2026

Mar 30, 2026

Protara reports 68.0% six-month CR rate in 25 BCG-unresponsive patients, warrants exercisable through June 29, 2026 - TradingView

Mar 30, 2026

Mar 30, 2026

Protara Therapeutics (TARA) sustains 68% CR in ADVANCED-2 and activates $5.25 warrants - Stock Titan

Mar 30, 2026